» Articles » PMID: 39083807

Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells

Abstract

Relapse rates in high-risk neuroblastoma remain exceedingly high. The malignant cells that are responsible for relapse have not been identified, and mechanisms of therapy resistance remain poorly understood. In this study, we used single-nucleus RNA sequencing and bulk whole-genome sequencing to identify and characterize the residual malignant persister cells that survive chemotherapy from a cohort of 20 matched diagnosis and definitive surgery tumor samples from patients treated with high-risk neuroblastoma induction chemotherapy. We show that persister cells share common mechanisms of chemotherapy escape, including suppression of MYC(N) activity and activation of NFκB signaling, and the latter is further enhanced by cell-cell communication between the malignant cells and the tumor microenvironment. Overall, our work dissects the transcriptional landscape of cellular persistence in high-risk neuroblastoma and paves the way to the development of new therapeutic strategies to prevent disease relapse. Significance: Approximately 50% of patients with high-risk neuroblastoma die of relapsed refractory disease. We identified the malignant cells that likely contribute to relapse and discovered key signaling pathways that mediate cellular persistence. Inhibition of these pathways and their downstream effectors is postulated to eliminate persister cells and prevent relapse. See related commentary by Wolf et al., p. 2308.

Citing Articles

Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma.

Fu S, Du H, Dai Y, Zheng K, Cao G, Xu L iScience. 2024; 27(12):111437.

PMID: 39717085 PMC: 11664176. DOI: 10.1016/j.isci.2024.111437.

References
1.
Louault K, Blavier L, Lee M, Kennedy R, Fernandez G, Pawel B . Nuclear factor-κB activation by transforming growth factor-β1 drives tumour microenvironment-mediated drug resistance in neuroblastoma. Br J Cancer. 2024; 131(1):90-100. PMC: 11231159. DOI: 10.1038/s41416-024-02686-8. View

2.
Lorenzi S, Forloni M, Cifaldi L, Antonucci C, Citti A, Boldrini R . IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One. 2012; 7(10):e46928. PMC: 3465322. DOI: 10.1371/journal.pone.0046928. View

3.
Kumar A, Negi G, Sharma S . JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 2011; 13(8):750-8. DOI: 10.1111/j.1463-1326.2011.01402.x. View

4.
Zhang P, Wu X, Basu M, Dong C, Zheng P, Liu Y . Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An Immunological Analysis of TARGET Database. Front Immunol. 2017; 8:1473. PMC: 5675839. DOI: 10.3389/fimmu.2017.01473. View

5.
Borriello L, Nakata R, Sheard M, Fernandez G, Sposto R, Malvar J . Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res. 2017; 77(18):5142-5157. PMC: 5600847. DOI: 10.1158/0008-5472.CAN-16-2586. View